Grifols (NASDAQ:GRFS) Stock Passes Below 200-Day Moving Average – Here’s Why

Grifols, S.A. (NASDAQ:GRFS) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $8.37 and traded as low as $7.13. Grifols shares last traded at $7.21, with a volume of 976,362 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GRFS. Weiss Ratings cut Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Grifols has a consensus rating of “Reduce” and a consensus price target of $10.00.

Grifols Stock Performance

The business’s 50-day moving average price is $7.64 and its 200-day moving average price is $8.36. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47. The stock has a market cap of $4.96 billion, a P/E ratio of 38.37, a P/E/G ratio of 0.28 and a beta of 0.67.

Grifols Announces Dividend

The business also recently announced a special dividend, which will be paid on Thursday, July 9th. Investors of record on Thursday, July 2nd will be given a dividend of $0.0945 per share. The ex-dividend date is Thursday, July 2nd. Grifols’s payout ratio is 121.05%.

Institutional Trading of Grifols

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can lifted its position in shares of Grifols by 3,205.1% during the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock valued at $30,017,000 after buying an additional 2,922,540 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Grifols by 383.7% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after acquiring an additional 2,221,633 shares during the period. Norges Bank bought a new position in shares of Grifols during the 4th quarter valued at approximately $18,139,000. Brandes Investment Partners LP increased its holdings in Grifols by 6.3% in the 4th quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after acquiring an additional 1,838,727 shares in the last quarter. Finally, Barclays PLC increased its holdings in Grifols by 132.6% in the 4th quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after acquiring an additional 1,387,783 shares in the last quarter.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.